Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 13/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374581 | 0.85 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL11258920 | 0.79 | HPRT1 (0.69) | HPRT1PNP | |
| SCHEMBL7398699 | 0.79 | HPRT1 (0.54) | HPRT1PNP | |
| SCHEMBL24239249 | 0.79 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL1993930 | 0.79 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL7569894 | 0.78 | HPRT1 (0.58) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL3060815 | 0.78 | HPRT1 (0.63) | HPRT1PNP | |
| SCHEMBL455494 | 0.78 | PNP (0.64) | HPRT1ALDH1A1PNPMEN1LMNA | |
| SCHEMBL20782416 | 0.76 | HPRT1 (0.65) | HPRT1PNP | |
| SCHEMBL2979895 | 0.76 | MEN1 (0.68) | HPRT1PNPMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238595-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | HPRT1 3808/4885KDM4E 4577/4885ALDH1A1 4860/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | HPRT1 3808/4885KDM4E 4577/4885ALDH1A1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.